Stocktoria
ACHIEVE LIFE SCIENCES, INC. ACHV
Nasdaq · XNAS · stock · In Vitro & In Vivo Diagnostic Substances · website · IPO 1995-10-12
ACHIEVE LIFE SCIENCES, INC. financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| R&D expense | — | $22.8M | $15.8M | $30.1M | $24.0M |
| Interest expense | — | — | $2.9M | $1.8M | — |
| Net income | -$54.6M | -$39.8M | -$29.8M | -$42.4M | -$33.2M |
| EPS (diluted) | $-1.25 | $-1.24 | $-1.50 | $-4.00 | $-4.08 |
| Operating cash flow | -$49.5M | -$29.8M | -$24.5M | -$37.6M | -$29.4M |
| Free cash flow | -$49.5M | — | -$24.5M | — | — |
| Cash & equivalents | $20.9M | $12.8M | $15.5M | $24.8M | $43.0M |
| Total assets | $41.8M | $38.6M | $19.4M | $30.0M | $47.5M |
| Total liabilities | $20.3M | $17.7M | $20.8M | $21.7M | $19.5M |
| Shareholders' equity | $21.5M | $20.9M | -$1.4M | $8.3M | $28.0M |
Source: SEC EDGAR filings · CIK 0000949858 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.